Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Biocrucible Logo
Biocrucible Growth Score
84
CB Rank
430159
Heat Score
59
Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation.
Acquired by
Sapphiros Logo
Sapphiros
Founded
obfuscation
Private Cambridge, Massachusetts, United States11-50 www.biocrucible.co.uk
Biotechnology
Health Diagnostics
Overview

Biocrucible
Growth Score
84
Heat Score
59

Growth Score84
-4 pts
in past quarter
Heat Score 59
-8 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About Biocrucible

CB Rank
430159
Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation.
Acquired by
Sapphiros Logo
Sapphiros
Founded
obfuscation
Private Cambridge, Massachusetts, United States11-50 www.biocrucible.co.uk
Biotechnology
Health Diagnostics

Key People

Details

Operating Status Active
Company Type For Profit
About the Company
Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation.
Phone Number +44 (0) 1223 792467
Contact Email info@biocrucible.co.uk
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Isothermal Nucleic Acid Amplification Molecular Diagnostic Platform
A molecular diagnostic platform using proprietary isothermal nucleic acid amplification technology for rapid detection of infectious diseases and genetic markers near-patient or at home.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

M&A Details

Biocrucible was acquired by Sapphiros on
obfuscation
.
Transaction Name 
Biocrucible acquired by Sapphiros Logo
Biocrucible acquired by Sapphiros
Acquired by 
Sapphiros Logo
Sapphiros
Announced Date 
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 2 Contacts 43

Employee Profiles

News

News and Press

News•Jan 20, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Oct 5, 2021
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

IT Spend

$56.8KThis year, Biocrucible is projected to spend $56.8K on IT, according to Aberdeen.

Active Website Tech Count

6Biocrucible is actively using 6 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m, IIS 10, and  IIS.

Total IP

5Biocrucible has registered 5 trademarks with the most popular class being 'Chemical substances', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Biocrucible's headquarters? Biocrucible is located in Cambridge, Massachusetts, United States.Who are Biocrucible's competitors? Alternatives and possible competitors to Biocrucible may include Visby Medical, Abbott, and  QuidelOrtho.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(6ec160d 1)
|